Search 

Accucaps Industries specializes in soft gel formulations and operates a full R&D organization, developing and supporting projects from early research to life cycle management. We are continually engaged with potential partners in exploring how our broad therapeutic portfolio, formulation, clinical development and manufacturing expertise combined with strong customer relationships, can yield mutually beneficial business relationships.

Our Product Innovation team has developed technologies which may enhance bioavailability through advanced technologies incorporated into the design of various formulation solutions within soft gel capsules.  Some of these technologies may assist your organization in maintaining their leading position with their top products through additional lifecycle options.

AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Our lead product, ARX-01, is currently being evaluated in Phase 3 studies for the treatment of moderate to severe acute pain in the hospital setting. ARX-01 is designed to enable patient control, remove impediments to ambulation, and improve patient satisfaction. By utilizing sublingual delivery of sufentanil NanoTabs(R) thorugh our proprietary handheld system, ARX-01 avoids the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. By delivering sufentanil through the oral transmucosal route, ARX-01 offers the potential to improve upon the typical side effect profile of morphine. 

We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.

Acorda Therapeutics, Inc. is a biotechnology company whose mission is to develop and market therapies that restore neurological function and improve the lives of people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company's marketed products include AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. and ZANAFLEX CAPSULES® (tizanidine hydrochloride). AMPYRA® is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. ZANAFLEX CAPSULES® is a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Alberta’s life science sector is strong and vibrant. It is comprised of 130 bioindustry companies concentrated in health, medical device applications, industrial bioproducts and agriculture biotechnology that directly employ more than 4,700 people.

Alberta is home to three research intensive academic institutions:

University of Alberta (www.ualberta.ca)

University of Calgary (www.ucalgary.ca)

University of Lethbridge (www.uleth.ca)

EXCEPTIONAL PROVINCIAL SUPPORT

Alberta Enterprise Corporation - $100 million to stimulate venture capital

Polaris Awards - to attract world leading researchers ($20 million each)

Alberta Nanotechnology Strategy ($150 million)

Newly integrated research and innovation system

OUR AREAS OF EXPERTISE

Today we apply this impressive expertise and knowledge across a wide range of sectors with internationally renowned researchers and companies in:

Infectious Diseases

Cardiology

Neurobiology

Diabetes

Oncology

Obesity

Nanotechnology

AlloCure is a Boston-based biotechnology company developing AC607, an allogeneic mesenchymal stem cell therapy for the treatment acute kidney injury (AKI) with potential applications in other grievous illnesses. 

Building on the success of a phase 1 clinical trial, AlloCure has initiated ACT-AKI, a randomized, multicenter, double-blind, placebo-controlled phase 2 trial in cardiac surgery subjects with post-operative AKI. Currently, there are no available treatment options for patients with AKI other than supportive care. AC607 represents the first application of a cell therapy to alter the course of this life threatening condition.